Rabbitpox: A model of airborne transmission of smallpox

Journal of General Virology

Volumn 92, Issue 1, 2011, Pages 31-35

  Nalca, Aysegul ^a   Nichols, Donald K ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE; TECOVIRIMAT;

AEROSOL; AIRBORNE VIRUS; ANIMAL MODEL; GENE SEQUENCE; HISTOLOGY; HUMAN; INCUBATION TIME; INFLAMMATION; LUNG LESION; NECROSIS; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RABBIT; RABBITPOX; REVIEW; SMALLPOX; SMALLPOX VIRUS; VIREMIA; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION;

AIR MICROBIOLOGY; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; POXVIRIDAE INFECTIONS; RABBITS; RODENT DISEASES; VACCINIA VIRUS;

ANIMALIA; ORTHOPOXVIRUS; ORYCTOLAGUS CUNICULUS; RABBITPOX VIRUS; VARIOLA VIRUS;

EID: 78651258933     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.026237-0     Document Type: Review

References (42)

1. Adams, M. M., Rice, A. D. & Moyer, R. W. (2007). Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 81, 11084-11095.
2. Bedson, H. S. & Duckworth, M. J. (1963). Rabbit pox: an experimental study of the pathways of infection in rabbits. J Pathol Bacteriol 85, 1-20.
3. Bras, G. (1952a). The morbid anatomy of smallpox. Doc Med Geogr Trop 4, 303-351.
4. Bras, G. (1952b). Observation on the formation of smallpox scars. AMA Arch Pathol 54, 149-156.
5. Bray, M., Martinez, M., Kefauver, D., West, M. & Roy, C. (2002). Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 54, 129-142.
6. Chapman, J. L., Nichols, D. K., Martinez, M. J. & Raymond, J. W. (2010). Animal models of orthopoxvirus infection. Vet Pathol 47, 852-870.
7. Christensen, L. R., Bond, E. & Matanic, B. (1967). "Pock-less" rabbit pox. Lab Anim Care 17, 281-296.
8. Councilman, W. T., Magrath, G. B. & Brincherhoff, W. R. (1904). The pathological anatomy and histology of Variola. J Med Res 11, 12-135.
9. Fenner, F. (1958). The biological characters of several strains of vaccinia, cowpox and rabbitpox. Virology 5, 502-529.
10. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988a). The pathogenesis, pathology and immunology of smallpox and vaccinia. In Smallpox and its Eradication, pp. 121-168. Geneva: World Health Organization.
11. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988b). Smallpox vaccine and vaccination in the intensified smallpox eradication programme. In Smallpox and its Eradication, pp. 539-592. Geneva: World Health Organization.
12. Garza, N. L., Hatkin, J. M., Nichols, D. K., Livingston, V. & Nalca, A. (2009). Evaluation of efficacy of modified vaccinia virus (MVA) vaccine against aerosolized rabbitpox virus. Vaccine 27, 5496-5504.
13. Greene, H. S. N. (1933). A pandemic of rabbit-pox. Proc Soc Exp Biol Med 30, 892-894.
14. Greene, H. S. N. (1934a). Rabbit pox, I. Clinical manifestations and course of disease. J Exp Med 60, 427-440.
15. Greene, H. S. N. (1934b). Rabbit pox: II. Pathology of the epidemic disease. J Exp Med 60, 441-455.
16. Greene, H. S. N. (1935). Rabbit pox: III. Report of an epidemic with especial reference to epidemiological factors. J Exp Med 61, 807-831.
17. Henderson, D. A. (1999). The looming threat of bioterrorism. Science 283, 1279-1282.
18. Henderson, D. A. (2002). Countering the posteradication threat of smallpox and polio. Clin Infect Dis 34, 79-83.
19. Huggins, J., Goff, A., Hensley, L., Mucker, E., Shamblin, J., Wlazlowski, C., Johnson, W., Chapman, J., Larsen, T. & other authors (2009). Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 53, 2620-2625.
20. Hutson, C. L., Olson, V. A., Carroll, D. S., Abel, J. A., Hughes, C. M., Braden, Z. H., Weiss, S., Self, J., Osorio, J. E. & other authors (2009). A prairie dog animal model of systemic Orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 90, 323-333.
21. Jansen, J. (1941). Todliche infektionen von kanichen durch ein filtrierbares virus. Zbl Bakt Parasit Infekt 148, 65-68 (in German).
22. Jansen, J. (1947). Immuniteitsproblemen betreffende konijnen-pest. Tijdschr Diergeneeskd 72, 550-557 (in Dutch).
23. Jordan, R., Goff, A., Frimm, A., Corrado, M. L., Hensley, L. E., Byrd, C. M., Mucker, E., Shamblin, J., Bolken, T. C. & other authors (2009). ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 53, 1817-1822.
24. Lancaster, M. C., Boulter, E. A., Westwood, J. C. N. & Randles, J. (1966). Experimental respiratory infection with poxviruses. II: Pathological studies. Br J Exp Pathol 47, 466-471.
25. Li, G., Chen, N., Roper, R. L., Feng, Z., Hunter, A., Danila, M., Lefkowitz, E. J., Buller, R. M. L. & Upton, C. (2005). Complete coding sequences of the rabbitpox virus genome. J Gen Virol 86, 2969-2977.
26. Nalca, A., Hatkin, J. M., Garza, N. L., Nichols, D. K., Hurby, D. E. & Jordan, R. (2008). Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79, 121-127.
27. Nichols, D. K., Nalca, A. & Roy, C. J. (2006). Pathology of aerosolized rabbitpox virus infection in rabbits. Vet Pathol 43, 831.
28. Pearce, L., Rosahn, P. D. & Hu, C. K. (1936). Studies on the etiology of rabbit pox: V. Studies on species susceptibility to rabbit pox virus. J Exp Med 63, 491-507.
29. Quenelle, D. C., Buller, R. M., Parker, S., Keith, K. A., Hruby, D. E., Jordan, R. & Kern, E. R. (2007a). Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 51, 689-695.
30. Quenelle, D. C., Prichard, M. N., Keith, K. A., Hruby, D. E., Jordan, R., Painter, G. R., Robertson, A. & Kern, E. R. (2007b). Synergistic efficacy of the combination ST-246 with CMX001 against orthopox-viruses. Antimicrob Agents Chemother 51, 4118-4124.
31. Rosahn, P. D. & Hu, C. (1935). Rabbit pox report of an epidemic. J Exp Med 62, 331-347.
32. Rosahn, P. D., Hu, C. & Pearse, L. (1936). Studies on the etiology of rabbitpox II. Clinical characteristics of the experimentally induced disease. J Exp Med 63, 259-276.
33. Sbrana, E., Xiao, S. Y., Newman, P. C. & Tesh, R. B. (2007a). Comparative pathology of North American and central African strains of monkeypox virus in a ground squirrel model of the disease. Am J Trop Med Hyg 76, 155-164.
34. Sbrana, E., Jordan, R., Hruby, D. E., Mateo, R. I., Xiao, S. Y., Siirin, M., Newman, P. C., Rosa, A. P. A. T. D. & Tesh, R. B. (2007b). Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 76, 768-773. (Pubitemid 351627722)
35. Schriewer, J., Buller, R. M. & Owens, G. (2004). Mouse models for studying orthopoxvirus respiratory infections. Methods Mol Biol 269, 289-308.
36. Schultz, D. A., Sagartz, J. E., Huso, D. L. & Buller, R. M. L. (2009). Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 383, 86-92.
37. Smee, D. F. (2008). Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 19, 115-124.
38. Smee, D. F., Bailey, K. W., Wong, M. H. & Sidwell, R. W. (2001). Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 52, 55-62.
39. Stabenow, J., Buller, R. M., Schriewer, J., West, C., Sagartz, J. E. & Parker, S. (2010). A mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus. J Virol 84, 3909-3920.
40. Thomas, G. (1970). Sampling rabbit pox aerosols of natural origin. J Hyg (Lond) 68, 511-517.
41. Westwood, J. C. N., Boulter, E. A., Bowen, E. T. W. & Maber, H. B. (1966). Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol 47, 453-465.
42. Yang, G., Pevear, D. C., Davies, M. H., Collett, M. S., Bailey, T., Rippen, S., Barone, L., Burns, C. & Rhodes, G. & & other authors (2005). An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 79, 13139-13149.